Study of Intraventricular Cerliponase Alfa for CLN2 Disease
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
Background Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. Methods In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). Results Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [148]
Citations
Cites
Sleat, D. E., Donnelly, R. J., Lackland, H., Liu, C.-G., Sohar, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationSleat, D. E., Gin, R. M., Sohar, I., Wisniewski, K., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 178
Steinfeld, R., Heim, P., von Gregory, H., Meyer, K., Ullrich, K., Goebel, H. H., & Kohlschütter, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10660 · Cited by 178
Self-citationThe Genetic Spectrum of Human Neuronal Ceroid‐lipofuscinoses
Mole, S. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00500.x · Cited by 115
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
Worgall, S., Kekatpure, M. V., Heier, L., Ballon, D., Dyke, J. P., Shungu, D., Mao, X., Kosofsky, B., Kaplitt, M. G., Souweidane, M. M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267885.47092.40 · Cited by 112
Self-citationKatz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Kishnani, P. S., Dickson, P., Muldowney, L., Lee, J. J., Rosenberg, A. S., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M. C., Freitas, A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.11.001 · Cited by 95
Vuillemenot, B. R., Katz, M. L., Coates, J. R., Kennedy, D., Tiger, P. M. N., Kanazono, S., Lobel, P., Sohár, I., Xu, S., Cahayag, R., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.018 · Cited by 81
Vuillemenot, B. R., Kennedy, D., Cooper, J. D., Wong, A. M. S., Sri, S., Doeleman, T., Katz, M. L., Coates, J. R., Johnson, G. C., Reed, R. P., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.004 · Cited by 60
Research works printed but not linked: 1
- Mole SE, Williams RE, Goebe HH, eds. The neuronal ceroid lipofuscinoses (Batten disease). 2nd ed. Oxford, England: Oxford University Press, 2011.
Cited by
Items 401–498 of 498
Takahashi, K., Eultgen, E. M., Wang, S. H., Rensing, N. R., Nelvagal, H. R., Dearborn, J. T., Sands, M. S., Wong, M., & Cooper, J. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.11.483984
“Although ERT slows CLN2 disease progression[9], cerliponase alfa is not curative and requires bi-weekly life-long administration.”
BackgroundGenetic Testing for Rare Diseases
Millán, J. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3727-6
Fine, E. J., Langan, E., Lohr, L. A., & Mages, K. C. (2018) · Journal of the History of the Neurosciences · doi:10.1080/0964704x.2018.1528131
Kinarivala, N., Morsy, A., Patel, R., Carmona, A. V., Sajib, M. S., Raut, S., Mikelis, C. M., Al-Ahmad, A. J., & Trippier, P. C. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11493132
Neurodegenerative Erkrankungen der grauen Hirnsubstanz
Kohlschütter, A. (2018) · Springer Reference Medizin · doi:10.1007/978-3-642-54671-6_254-2
Self-citationDeegan, P. B., & Cox, T. M. (2020) · doi:10.1093/med/9780198746690.003.0235
Effect of CLN3-loss-of-function on cellular metabolism and signalling
Więciorek-Płuciennik, K. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9277
Singer, H. S., Mink, J. W., Gilbert, D. L., & Jankovic, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820552-5.00006-1
Neuronal Ceroid Lipofuscinosis Type 2: A Case Series from Argentina
Guelbert, G., & Guelbert, N. B. (2022) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2022-0001
Genetische Aspekte kindlicher Epilepsiesyndrome
Syrbe, S. (2022) · Kinder- und Jugendmedizin · doi:10.1055/a-1915-9895
Anti-convulsant Agents: Beginning and Duration of Therapy, Withdrawal, and Resistance – Children
Borggraefe, I. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_371
Optimizing Therapy of Seizures in Children and Adolescents with Developmental Disabilities
Fine, A. L., Wirrell, E. C., & Nickels, K. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-20792-1_39
The diagnostic challenges presented in a patient with neuronal ceroid lipofuscinosis type 2
Белоусова, Е. Д., Mikhaylova, S. V., & Zakharova, E. Y. (2023) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2023-68-1-30-46
A mouse mutant deficient in both neuronal ceroid lipofuscinosis‐associated proteins CLN3 and TPP1
Sleat, D. E., Banach-Petrosky, W. A., Larrimore, K. E., Nemtsova, Y., Wiseman, J. A., Najafi, A. R., Johnson, D., Poole, T. A., Takahashi, K., Cooper, J. D., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12619 · Cited by 1
Overview of the Current Real-World Evidence Regulatory Landscape
Izem, R., Davi, R. C., Luan, J. J., & Gamalo, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26328-6_2
Neurodegeneation treatment in lysosomal diseases. An update
García-Navarrete, S., & Gil‐Campos, M. (2022) · ACTUALIDAD MEDICA · doi:10.15568/am.2022.816.rev01 · Cited by 1
Current Therapies for Neuronal Ceroid Lipofuscinosis
Richa, F. (2023) · Annals of Reviews & Research · doi:10.19080/arr.2023.08.555743
Comment: Amenable Treatable Severe Pediatric Epilepsies
Pearl, P. L. (2023) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2023.101073
Nakashima, S., Hamada, M., Kimura, T., Tanifuji, S., Takahashi, A., Yashita, D., Kakimoto, Y., Matsukawa, T., Ishiura, H., & Toda, T. (2023) · Internal Medicine · doi:10.2169/internalmedicine.2563-23
“It has been shown that 96% of patients had convulsions, and 17% had epilepsy as a side effect of cerliponase alfa (5).”
BackgroundResultJansky-Bielschowsky Disease in 2 Moroccan Girls. Clinical Cases
Abdelhakim, O., Babour, S., Abilkassem, R., Amale, H., Mohamed, K., & Aomar, A. (2023) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2023.v11i11.033
Targeted Drug Delivery to the CNS: Beyond the Intrathecal Space
Abrams, D. J., & Stewart, G. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_24
Explorations Multi-omiques dans les maladies neuromusculaires
Dabaj, I. (2023) · theses.fr (ABES) · doi:10.70675/120670afz0b80z472dzb00bz95793dadb289
Therapeutic strategies based on genetic interventions
Baek, R. C., Finn, P. F., & Martini, P. G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00013-6
Pastores, G. M., & Tay, S. K. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00007-0
El valor del medicamento desde una perspectiva social 2024
(2024) · Fundación Weber eBooks · doi:10.37666/l27-2024 · Cited by 1
Differential aspects of orphan drugs and their value from a social perspective
Hidalgo, A., Fernández, I., Villaseca, J., Abdalla, F., & Zozaya, N. (2024) · doi:10.37666/i22-2024
Rana dijagnoza neuronske* ceroidne lipofuscinoze tip 2 - mit ili stvarnost?
Prpić, I. (2021) · Paediatria Croatica · doi:10.13112/pc.385
A gray area: Gray matter disease in leukodystrophies
Al‐Saady, M. L. (2024) · doi:10.5463/thesis.775
Fonzo, A. D., & Maio, A. D. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.009
Joshi, S., & Lal, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-77741-7_9
8. How can real-world data, registries, and databases address the challenges of rare diseases?
Mole, S., Gardner, E., & Mason, H. L. (2025) · Medical Writing · doi:10.56012/kwle5627
SUDEP in inherited metabolic epilepsies
Latzer, I. T., Adams, C., Lapham, G., Buchhalter, J., & Pearl, P. L. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110422
Inherited Metabolic Epilepsies
Latzer, I. T., & Pearl, P. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00097-4
A Rare Case of CLN3-associated Isolated Retinal Degeneration with Macular Oedema
Kalogeropoulos, D., Khandhadia, S., Shawkat, F. S., & Lotery, A. J. (2025) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2577-9808
Drug Delivery Modalities and Mechanisms
Tam, Y. T., Migliozzi, M. M., Tesar, D. B., Famili, A., Wecksler, A. T., Wichner, S. M., Sreedhara, A., & Shatz-Binder, W. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch20
Cerliponase Alfa for Pediatric Patients With Neuronal Ceroid Lipofuscinosis Type 2 Disease
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1144
Unraveling Neuronal Ceroid Lipofuscinosis: Insights From Two Pediatric Cases in Peripheral India
Aman, N., Panapil, A., & Utage, P. (2025) · Journal of Child Neurology · doi:10.1177/08830738251346920
Thérapie innovante dans la maladie CLN2 : nouvelles trajectoires, nouveaux enjeux éthiques ?
Saucier, É., David, I., Dufour, L., Auvin, S., & Mourman, V. (2025) · Médecine Palliative · doi:10.1016/j.medpal.2025.06.003
Cerliponasa alfa en lipofuscinosis neuronal ceroidea de tipo 2
Vaca, P. R. (2025) · Panorama actual del medicamento · doi:10.63105/49.485.6
Schinzel-Giedion syndrome: communication, feeding and motor skills in 16 individuals
Morison, L. D., Summerfield, N. J., Bradley, D., van Bon, B. W. M., & Morgan, A. T. (2025) · Neurogenetics · doi:10.1007/s10048-025-00846-3
Kagawa, Y., Osawa, T., Koyama, N., Tanaharu, T., & Kigami, D. (2025) · Current Research in Toxicology · doi:10.1016/j.crtox.2025.100258 · Cited by 1
“…of the three DART studies: FEED, EFD, or PPND. CLN2 is an ultra-rare, severe genetic disorder associated with progressive neurodegeneration and is characterized by a deficiency in the lysosomal serine protease tripeptidyl peptidase 1 (Nickel et al., 2018; Worgall et al., 2007; Schulz et al., 2018).”
New Insights into Batten Disease CLN1 from a Patient Facing RegistryPreprint
Ekins, S., Snyder, S. H., Tojong, M., Lane, T. R., Hamilton, M., & Reyes, E. D. L. (2025) · medRxiv · doi:10.1101/2025.09.25.25336690
Choosing an Index Date for Untreated Patients in External Comparator Studies
Antunes, L., Rippin, G., Ralphs, E., Luguzis, A., Arnold, K. F., & Lee, H. (2025) · Drug Safety · doi:10.1007/s40264-025-01613-x
“For supporting information, an exploratory survival analysis was performed to compare trial data against a natural history study cohort [26, Table 10, pp 66+82].”
Kitakaze, K., Ohnishi, Y., Tsuji, D., Watanabe, R., Kamori, N., Katakai, Y., Shibata, H., Yoshizawa, S., Ito, M., Takino, N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102762
Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.02.680174
“While there is currently no cure for CLN2 disease, early intervention of the Enzyme replacement therapy (ERT) of the human TPP1 proenzyme was shown to alleviate disease progression 8 .”
Batten disease: therapeutic agents
Kolotilov, M. M. (2025) · Likarska sprava · doi:10.31640/ls-2025-4-04
Nishizawa, Y., Nishikura, N., Morimune, T., Sobajima, H., Maruo, Y., Nakashima, M., Saitsu, H., Matsumoto, N., & Kato, M. (2025) · Brain and Development Case Reports · doi:10.1016/j.bdcasr.2025.100114
Trial Readiness: Understanding the Natural History of Rare Diseases
Opladen, T., Mütze, U., Gleich, F., Garbade, S. F., Hübschmann, O. K., Zielonka, M., & Kölker, S. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70102
“…trials [SAT]), particularly in rare IMDs, where traditionally designed RCTs are often infeasible due to the inability to recruit enough patients or the unwillingness of patients or trial leaders to randomly assign anyone to placebo, as in ceroid lipofuscinosis type 2 (CLN2) Batten disease [36].”
Major study types with designs, measures, and examples
Abdelrashid, M., & Lobbous, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90509-1.00041-2
Nguyen-Martinez, A. L., Jolliffe, M., Scimeca, L. M., Park, K., Demarest, S., Knupp, K. G., Angione, K. M., & Miele, A. S. (2025) · Child Neuropsychology · doi:10.1080/09297049.2025.2591632
“Brineura (Schulz et al., 2018), for example, is an FDA-approved ERT for children with CLN2 Batten disease, delivering the missing enzyme cerliponase alfa directly into the brain via biweekly intraventricular infusions.”
Gissen, P., Specchio, N., Olaye, A., Jain, M., Butt, T., Ghosh, W., Ruban‐Fell, B., Griffiths, A., Camp, C., Sisic, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14583637
Self-citationHoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046819
Amadori, E., Scala, M., Cereda, G. S., Vari, M. S., Marchese, F., Pisa, V. D., Mancardi, M. M., Giacomini, T., Siri, L., Vercellino, F., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12618174
Mole, S., Schulz, A., Badoe, Ë., Berkovic, S. F., Reyes, E. D. L., Dulz, S., Gissen, P., Guelbert, N. B., Lourenco, C. M., Mason, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14463028
Self-citationHoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046816
Mole, S., Schulz, A., Badoe, Ë., Berkovic, S. F., Reyes, E. D. L., Dulz, S., Gissen, P., Guelbert, N. B., Lourenco, C. M., Mason, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14463031
Self-citationHoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046813
Hoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046810
Domowicz, M. S., Chan, W.-C., Vázquez, P. N. C., Gonzalez, T., & Schwartz, N. B. (2021) · Figshare · doi:10.6084/m9.figshare.16960276
Hoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046822
van Konijnenburg, E. M. M. H., Wortmann, S. B., Koelewijn, M. J., Tseng, L. A., Houben, R. F. A., Stöckler‐Ipsiroglu, S., Ferreira, C. R., & van Karnebeek, C. (2021) · Figshare · doi:10.6084/m9.figshare.14404123
Hoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Figshare · doi:10.6084/m9.figshare.13046825
Guelbert, N., Segura, O. M. E., Amoretti, C. F., Arteaga, A. A., Atanacio, N. G., Bazan, N. S., Carvalho, E. D. F., de Andrade, M. D. F. C., Denzler, I. M., Durand, C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2159184/v1
Serliponaasi alfa : Fimea HTA-arviointikooste
Wikman, E., & Kiviniemi, V. V. (2021) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
Cherchi, F. (2021) · Florence Research (University of Florence)
Hersheson, J. (2024) · UCL Discovery (University College London)
PROGRESSIVE MYOCLONUS-ATAXIA SYNDROMES: DIAGNOSTIC CHALLENGES AND PRACTICAL APPROACHES
Wojdat-Krupa, K., Sikora, K., Lewaśkiewicz, P., Lachowski, F. R., Wasyluk, M., Babiński, P. J., & Jalali, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4202
“[ 19]EEG reveals abnormalities, including enhanced photo-paroxysmal responses at low-frequency light stimulation (1 – 2 Hz), abnormal background activity, and seizure-like discharges, with changes often more pronounced during awake and asleep recordings and diminishing as disease progresses [20].”
Historical control: Design, measures, classical example
Rinker, B. D., & Riley, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-91168-9.00098-3
CLN2 disease: why early diagnosis matters more than ever
Striano, P. (2026) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2026.03.001
Itoh, K., & Tsukimoto, J. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-04153-1_13
Ziółkowska, E., Nix, P., Olszowy, B., Williams, L. L., Eultgen, E. M., Nowacka, A., Celorrio, M., Friess, S. H., Heuckeroth, R. O., & Cooper, J. D. (2026) · Scientific Reports · doi:10.1038/s41598-026-49850-z
Chandra, S., & Pahan, K. (2026) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2026-0005
“Recently, ERT by intraventricular infusion of cerliponase alfa (recombinant human pro-TPP1) has been shown to reduce the impairment of locomotor functions and language impairment in children affected with CLN2 disease [26].”
Neurodegenerative Diseases in Children: A Comprehensive Review
Ailioaie, C., Ailioaie, L. M., Stan, C. I., Sava, A., & Chiran, D. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094096
Viewpoint: Decline in Speech and Language Skills May Signal Childhood Dementia
Morison, L. D., Elvidge, K., Scheffer, I. E., & Morgan, A. T. (2026) · American Journal of Speech-Language Pathology · doi:10.1044/2026_ajslp-25-00310
Whiteman, I. T., Villa, K. L., Spector, C. M., Cha, J.-H. J., Parker, A. F., Ahrens-Nicklas, R., Schulz, A., & Yohrling, G. J. (2026) · medRxiv · doi:10.64898/2026.05.31.26354557
Self-citationVermilion, J. A., Vierhile, A., Pereira-Frietas, M., Adams, H., Beausoleil, E., Albanis, E., & Mink, J. W. (2026) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2026.06.005
CLN2 Batten disease diagnosed via newborn genome screening
O’Connell, P., Fierro, L., Kaplan, R., Cohen, L. L., Chung, W. K., Orsini, J., & Ganesh, J. (2026) · Genetics in Medicine Open · doi:10.1016/j.gimo.2026.104415
Touzón, M. S., Valenzuela, G. R., Loos, M. A., Gonzalez, B., Gauto, A., Gomez, R. O., Andrade, Z. E. C., Rugilo, C., Princich, J. P., Aschettino, G., et al. (2026) · Seizure · doi:10.1016/j.seizure.2026.06.015
Phenotypic and Genetic Characterization of 64 Egyptian Children With Neuronal Ceroid Lipofuscinosis
Abdelkreem, E., Sadek, A. A., Aladawy, M. A., Rezk, Z. N., Salamah, A. M., Rafat, K., Magdy, R. M., Issa, M. Y., ElHadad, A. F., Elbendary, H. M., et al. (2026) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2026.07.005
Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses
Martakis, Κ., Abreu, N. J., Baker, J. J., Baker, P. R., II, Billington, I., Burrow, T. A., Factor, M. A., Fields, T., Fields, C., Gannon, J. L., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13984-x
“CLN2 patients receiving intracerebroventricular infusions of the enzyme replacement therapy cerliponase alfa, which attenuated the rate of motor decline, showed reduction in plasma NfL of 50% per year over a 3-year treat-ment period [50].”
Dearborn, J. T., Takahashi, K., Rensing, N. R., Wong, M., Cooper, J. D., & Sands, M. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0337880
“This treatment (Brineura enzyme replacement therapy) slows the progression of disease and improves some clinical symptoms [4].”
Recommendations for the use of clinical outcome assessments in rare disease drug development
Aiyegbusi, O. L., McCorry, N., Calvert, M., Peipert, J. D., Rivera, S. C., Muni‐Lofra, R., Alexis, S., Awan, F., Bailey, T., Billingham, L. J., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104073
“49 Another example is the FDA’s assessment, regulatory decision, and labelling of acoramidis for the treatment of adult patients with cardiomyopathy due to wild-type or variant transthyretin-mediated amyloidosis.”
InfluentialA new era of integration of genetics and neurology
Sen, K., Gropman, A., Cihan, C. K. E., Rajan, D. S., & Dang, L. T. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001606
Raman, R., Winsor, J., Case, K. C., Xia, J., Daly, T., Benscics, C., Turner, D., Horst, B., Karustis, L., Shahrokh, Z., et al. (2026) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2026.110240
Banning, A., Reznikova, L., Murad, A., & Tikkanen, R. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70248
“Over the past decade, there has been great progress in the development of ERT for lysosomal diseases, such as neuronal ceroid lipofuscinosis 2 (CLN2) [29], Fabry disease [30], Pompe disease [31] and others (for a review, see [27]).”
Mikhaylova, S. V., Kakaulina, V. S., Reshchikov, D. A., & Lobankin, P. V. (2026) · Russian Journal of Child Neurology · doi:10.17650/2073-8803-2026-21-2-103-114
Genetic Diagnosis in Epilepsy: Implications for Clinical Management
Schatz, K. S., Lammert, D. B., & Habela, C. W. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01514-1
“Cerliponase alpha is an FDA-approved tripeptidyl peptidase-1 replacement therapy for CLN2 that was shown to reduce the rate of motor and language decline [99–103 ].”
Occhipinti, S. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Gene therapy in neuronal ceroid lipofuscinosis (NCL)
Namini, M. S., Mousavi, S. A. R., & Kazemi, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00002-6
Gopalka, M., Manocha, S., Romanski, K., Hoeman, E., Boop, S. H., & Lam, S. K. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07463-x
“Intraventricular cerliponase alfa enzyme replacement therapy has altered the natural history of CLN2 by slowing neurologic deterioration and improving survival outcomes compared with untreated cohorts [6, 14, 15].”
Neuronal Ceroid Lipofuscinosis (NCL) Type 2
(2026) · Elsevier eBooks · doi:10.1016/b978-3-437-15042-5.00170-3
Specchio, N., Auvin, S., Bisulli, F., Demarest, S., Gardella, E., Kakooza‐Mwesige, A., Nabbout, R., Othman, A. S., Vinayan, K. P., Whitney, R., et al. (2026) · Epilepsia · doi:10.1002/epi.70467
Self-citationMorgan-Jack, B. R., Kick, G. R., Lyu, Z., Joshi, T., Mooney, B., Coates, J. R., Ota‐Kuroki, J., Katz, M. L., & Whiting, R. E. H. (2026) · Biology · doi:10.3390/biology15191761
“The only FDA-approved treatment for CLN2 disease is CNS enzyme replacement therapy [47].”
The role of the NLRP3 inflammasome in a CLN2 mouse model of neuroinflammationPreprint
Sanchez, K., Elizalde, S., Schwartz, N. B., & Domowicz, M. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.758052
“More specifically, preventing inflammasome assembly may slow down disease progression and offer a supplement to current treatment paradigms, such as enzyme replacement therapy (Schulz et al. 2018; de Brito Sampaio et al. 2023), in CLN2.”
Applications of enzyme activity assays in clinical development for rare disease therapeutics
Vrentas, C. E., Quadrini, K. J., & Ni, Y. G. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2744071
Advancing Evidence Generation in Small, Diverse, Understudied Population
Mitra, A., Dosne, A., Steinbach, D., Jones, H. M., Mondick, J. T., & Krishna, R. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70548
Metadata
- Authors
- Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., & Kohlschütter, A.
- Affiliations
- Nationwide Children's Hospital (US)
- From the Department of Pediatrics, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (A.S., A.K.); BioMarin Pharmaceutical, Novato, CA (T.A., H.C., P.S., D.J.); the Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome (N.S.); Nationwide Children’s Hospital and Ohio State University, Columbus (E.L.R.); UCL Great Ormond Street Institute of Child Health, London (P.G.); and the Citigroup Biomedical Imaging Center, Departments of Radiology and Genetic Medicine, Weill...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1898-1907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2799850385
- Cited by
- 489
- References
- 17
- Citations by year
- 2026: 36 · 2025: 57 · 2024: 37 · 2023: 49 · 2022: 86 · 2021: 74 · 2020: 83 · 2019: 47 · 2018: 17
- FWCI
- 37.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health Research
- European Union Seventh Framework Program Grand (281234)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- cerliponase alfa, CLN2 disease, neuronal ceroid lipofuscinosis type 2, intraventricular infusion, enzyme replacement therapy, tripeptidyl peptidase 1, lysosomal storage disease, pediatric patients, device-related infection, adverse events
- MeSH terms
- Tripeptidyl-Peptidase 1, Adolescent, Child, Child, Preschool, Dementia, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Female, Humans, Language Development, Male, Motor Skills, Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Disease Progression, Kaplan-Meier Estimate, Enzyme Replacement Therapy, Infusions, Intraventricular, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.